Copy For Citation
Sayan M., Gunduz A., Ersoz G., Inan A., Deveci A., Ozgur G., ...More
HIV CLINICAL TRIALS, vol.17, no.3, pp.109-113, 2016 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
17
Issue:
3
-
Publication Date:
2016
-
Doi Number:
10.1080/15284336.2016.1153303
-
Journal Name:
HIV CLINICAL TRIALS
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Page Numbers:
pp.109-113
-
Keywords:
Hiv-1 Integrase, Integrase Inhibitors, Raltegravir, Elvitegravir, Dolutegravir, Drug Resistance, Dna Sequencing, ANTIRETROVIRAL-NAIVE PATIENTS, NATURAL POLYMORPHISMS, HIV-1, INDIVIDUALS, THERAPY, UPDATE, TURKEY
-
Bursa Uludag University Affiliated:
Yes
Abstract
Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV) drugs designed to block the action of the integrase viral enzyme, which is responsible for insertation of the HIV-1 genome into the host DNA. The aim of this study was to evaluate for the first time INSTI resistance mutations in Turkish patients.